♥
ISIN : INE232I01014
NSE : SPARC
BSE : 532872
Face Value : 1
Industry : Miscellaneous
EPS : -11.93
EPS (TTM) : -11.95
Price to Earning (P/E) : -12.40
Book Value : 3.88
Price to Bookvalue (P/B) : 38.12
Dividend Yield : 0 %
Return on Equity (ROE) : -121.28 %
Return on Capital Employed (ROCE) : -112.35 %
Sun Pharma Advanced Research Company Limited
ISIN : INE232I01014
NSE : SPARC
BSE : 532872
Face Value : 1
Industry : Miscellaneous
EPS : -11.93
EPS (TTM) : -11.95
Price to Earning (P/E) : -12.40
Book Value : 3.88
Price to Bookvalue (P/B) : 38.12
Dividend Yield : 0 %
Return on Equity (ROE) : -121.28 %
Return on Capital Employed (ROCE) : -112.35 %
Sun Pharma share price(02-Apr-2026) | |
|---|---|
| Open / Close | 0 - 0 NAN % |
| Low / High | 0 - 0 NAN % |
| Trade Volume | 0 |
| 52 Week Low / High | 0 - 0 NAN % |
| Open / Close | 118.9 - 124.4 4.6 % |
| Low / High | 116.15 - 124.7 7.4 % |
| Trade Volume | 78,624 |
| 52 Week Low / High | 108.2 - 204.25 88.8 % |
-
YOU MAY ALSO LIKE
- Share Market basics for beginners
Share Market jargons in simple terms - High dividend stocks
High dividend yield stocks on Stock exchange NSE and BSE - How much money do you need to retire
Know how much money do you need to retire, before how much to invest ? - Stock market course tutorial
Stock Market Investment Course explained in simple words. - CAGR Calculator
Check your investment returns using our CAGR / Investment Growth Calculator - Low PE ratio stocks
Undervalued, low PE ratio stocks on Stock exchange NSE and BSE
CONSOLIDATED QUARTERLY RESULT FOR SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED
| Date End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| No of months | 3 months | 3 months | 3 months | 3 months | months | months | months | months | months | months |
| Net Sales | 211.8 | 138.6 | 165.6 | 168.1 | ||||||
| Total Income | 296.7 | 202.5 | 209.6 | 183.7 | ||||||
| Total Expenditure | 1126.5 | 1164.8 | 1223.9 | 1101.7 | ||||||
| Other Income | 84.9 | 63.9 | 44 | 15.6 | ||||||
| Operating Profit | -829.8 | -962.3 | -1014.3 | -918 | ||||||
| Interest | 2.6 | 2.6 | 9.1 | 5.6 | ||||||
| PBDT | -832.4 | -964.9 | -1023.4 | -923.6 | ||||||
| Depreciation | 31.8 | 31.6 | 30.7 | 31.4 | ||||||
| Profit Before Tax | -864.2 | -996.5 | -1054.1 | -955 | ||||||
| Tax | 3.8 | 4 | ||||||||
| Profit After Tax | -864.2 | -996.5 | -1057.9 | -959 | ||||||
| Net Profit | -864.2 | -996.5 | -1057.9 | -959 | ||||||
| Equity Capital | 324.5 | 324.5 | 324.5 | 324.5 | ||||||
| Face Value (IN RS) | 1 | 1 | 1 | 1 | ||||||
| Calculated EPS | -2.66 | -3.07 | -3.26 | -2.96 | ||||||
| Diluted Eps After Extraordinary Items | -2.66 | -3.07 | -3.26 | -2.96 | ||||||
| Diluted Eps Before Extraordinary Items | -2.66 | -3.07 | -3.26 | -2.96 |
STANDALONE QUARTERLY RESULT FOR SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED
| Date End | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| No of months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months |
| Net Sales | 252.4 | 284.6 | 315.4 | 1310.9 | 476.9 | 239.5 | 211.8 | 138.6 | 165.6 | 168.1 |
| Total Income | 254.6 | 286.4 | 316 | 1311.2 | 584.2 | 341.4 | 296.7 | 202.5 | 209.6 | 183.7 |
| Total Expenditure | 917.8 | 1066.6 | 941.4 | 1149.1 | 1372.6 | 1261.3 | 1126.5 | 1164.8 | 1240.8 | 1119.3 |
| Other Income | 2.2 | 1.8 | 0.6 | 0.3 | 107.3 | 101.9 | 84.9 | 63.9 | 44 | 15.6 |
| Operating Profit | -663.2 | -780.2 | -625.4 | 162.1 | -788.4 | -919.9 | -829.8 | -962.3 | -1031.2 | -935.6 |
| Interest | 22.2 | 16.3 | 28.6 | 29.3 | 2.1 | 2.6 | 2.6 | 2.6 | 8.8 | 5.2 |
| PBDT | -685.4 | -796.5 | -654 | 132.8 | -790.5 | -922.5 | -832.4 | -964.9 | -1040 | -940.8 |
| Depreciation | 25.1 | 27 | 30 | 31.3 | 29.4 | 31 | 31.8 | 31.6 | 26.9 | 27.6 |
| Profit Before Tax | -710.5 | -823.5 | -684 | 101.5 | -819.9 | -953.5 | -864.2 | -996.5 | -1066.9 | -968.4 |
| Profit After Tax | -710.5 | -823.5 | -684 | 101.5 | -819.9 | -953.5 | -864.2 | -996.5 | -1066.9 | -968.4 |
| Net Profit | -710.5 | -823.5 | -684 | 101.5 | -819.9 | -953.5 | -864.2 | -996.5 | -1066.9 | -968.4 |
| Equity Capital | 271.9 | 271.9 | 271.9 | 275.3 | 324.5 | 324.5 | 324.5 | 324.5 | 324.5 | 324.5 |
| Face Value (IN RS) | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Calculated EPS | -2.61 | -3.03 | -2.52 | 0.37 | -2.53 | -2.94 | -2.66 | -3.07 | -3.29 | -2.98 |
| Diluted Eps After Extraordinary Items | -2.69 | -3.03 | -2.52 | 0.35 | -2.55 | -2.94 | -2.66 | -3.07 | -3.29 | -2.98 |
| Diluted Eps Before Extraordinary Items | -2.69 | -3.03 | -2.52 | 0.35 | -2.55 | -2.94 | -2.66 | -3.07 | -3.29 | -2.98 |
CONSOLIDATED ANNUAL RESULT FOR SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED
| Date End | Mar 2024 | ||
|---|---|---|---|
| No of months | 12 months | months | months |
| Net Sales | 755.5 | ||
| Total Income | 1050.2 | ||
| Total Expenditure | 4776.5 | ||
| Other Income | 294.7 | ||
| Operating Profit | -3726.3 | ||
| Interest | 16.9 | ||
| PBDT | -3743.2 | ||
| Depreciation | 125.1 | ||
| Profit Before Tax | -3868.3 | ||
| Tax | 3.8 | ||
| Profit After Tax | -3872.1 | ||
| Net Profit | -3872.1 | ||
| Equity Capital | 324.5 | ||
| Face Value (IN RS) | 1 | ||
| Reserves | 933 | ||
| Calculated EPS | -11.93 | ||
| Diluted Eps After Extraordinary Items | -11.93 | ||
| Diluted Eps Before Extraordinary Items | -11.93 |
STANDALONE ANNUAL RESULT FOR SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED
| Date End | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|
| No of months | 12 months | 12 months | 12 months |
| Net Sales | 1372.5 | 2387.8 | 755.5 |
| Total Income | 1440.9 | 2496.6 | 1050.2 |
| Total Expenditure | 3240 | 4528.4 | 4793.4 |
| Other Income | 68.4 | 108.8 | 294.7 |
| Operating Profit | -1799.1 | -2031.8 | -3743.2 |
| Interest | 133.3 | 76.3 | 16.6 |
| PBDT | -1932.4 | -2108.1 | -3759.8 |
| Depreciation | 101.6 | 117.7 | 121.3 |
| Profit Before Tax | -2034 | -2225.8 | -3881.1 |
| Profit After Tax | -2034 | -2225.8 | -3881.1 |
| Net Profit | -2034 | -2225.8 | -3881.1 |
| Equity Capital | 271.9 | 324.5 | 324.5 |
| Face Value (IN RS) | 1 | 1 | 1 |
| Reserves | 40.4 | 4803.2 | 924 |
| Calculated EPS | -7.48 | -6.86 | -11.96 |
| Diluted Eps After Extraordinary Items | -7.73 | -7.82 | -11.96 |
| Diluted Eps Before Extraordinary Items | -7.73 | -7.82 | -11.96 |
CONSOLIDATED PROFIT / LOSS FOR SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED
| YEAR | Mar 2023 | Mar 2024 | ||
|---|---|---|---|---|
| No of Months | 12 months | 12 months | months | months |
| Gross Sales | 238.78 Cr | 75.55 Cr | 0 | 0 |
| Processing Charges / Service Income | 238.78 Cr | 75.55 Cr | 0 | 0 |
| Net Sales | 238.78 Cr | 75.55 Cr | 0 | 0 |
| Power & Fuel Cost | 5.75 Cr | 6.14 Cr | 0 | 0 |
| Electricity & Power | 5.75 Cr | 6.14 Cr | 0 | 0 |
| Employee Cost | 107 Cr | 141.84 Cr | 0 | 0 |
| Salaries, Wages & Bonus | 97.56 Cr | 129.38 Cr | 0 | 0 |
| Contributions to EPF & Pension Funds | 4.36 Cr | 5.62 Cr | 0 | 0 |
| Workmen and Staff Welfare Expenses | 3.11 Cr | 5.04 Cr | 0 | 0 |
| Other Manufacturing Expenses | 180.31 Cr | 140.23 Cr | 0 | 0 |
| Processing Charges | 3.57 Cr | 4.44 Cr | 0 | 0 |
| General and Administration Expenses | 154.91 Cr | 182.2 Cr | 0 | 0 |
| Rent , Rates & Taxes | 13.64 Lk | 38.01 Lk | 0 | 0 |
| Insurance | 75.94 Lk | 1.2 Cr | 0 | 0 |
| Printing and stationery | 8.63 Cr | 8.35 Cr | 0 | 0 |
| Professional and legal fees | 133.75 Cr | 155.86 Cr | 0 | 0 |
| Traveling and conveyance | 3.88 Cr | 5.22 Cr | 0 | 0 |
| Miscellaneous Expenses | 4.87 Cr | 7.23 Cr | 0 | 0 |
| Provision for doubtful debts | 0 | 2.05 Cr | 0 | 0 |
| Loss on disposal of fixed assets(net) | 11.29 Lk | 0 | 0 | 0 |
| Loss on foreign exchange fluctuations | 2.07 Cr | 3.1 Cr | 0 | 0 |
| Total Expenditure | 452.84 Cr | 477.64 Cr | 0 | 0 |
| Other Income | 10.88 Cr | 29.47 Cr | 0 | 0 |
| Interest Received | 7.6 Cr | 25.48 Cr | 0 | 0 |
| Profit on sale of Fixed Assets | 0 | 58.19 Lk | 0 | 0 |
| Operating Profit | -203.18 Cr | -372.63 Cr | 0 | 0 |
| Interest | 7.63 Cr | 1.69 Cr | 0 | 0 |
| Interest on Term Loan | 7.15 Cr | 15.69 Lk | 0 | 0 |
| Bank Charges etc | 0 | 50 Lk | 0 | 0 |
| PBDT | -210.81 Cr | -374.32 Cr | 0 | 0 |
| Depreciation | 11.77 Cr | 12.51 Cr | 0 | 0 |
| Profit Before Taxation & Exceptional Items | -222.58 Cr | -386.83 Cr | 0 | 0 |
| Profit Before Tax | -222.58 Cr | -386.83 Cr | 0 | 0 |
| Provision for Tax | 0 | 38.2 Lk | 0 | 0 |
| Current Income Tax | 0 | 1.63 Cr | 0 | 0 |
| Deferred Tax | 0 | -1.25 Cr | 0 | 0 |
| Profit After Tax | -222.58 Cr | -387.21 Cr | 0 | 0 |
| Consolidated Net Profit | -222.58 Cr | -387.21 Cr | 0 | 0 |
| Profit Balance B/F | -1370.58 Cr | -1591.81 Cr | 0 | 0 |
| Appropriations | -1593.17 Cr | -1979.03 Cr | 0 | 0 |
| Other Appropriation | -1.35 Cr | -18.74 Lk | 0 | 0 |
| Earnings Per Share | -6.86 | -11.93 | ||
| Adjusted EPS | -6.86 | -11.93 |
STANDALONE PROFIT / LOSS FOR SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED
| YEAR | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| No of Months | 12 months | 12 months | 12 months | 12 months |
| Gross Sales | 252.96 Cr | 137.25 Cr | 238.78 Cr | 75.55 Cr |
| Processing Charges / Service Income | 252.96 Cr | 137.25 Cr | 238.78 Cr | 75.55 Cr |
| Net Sales | 252.96 Cr | 137.25 Cr | 238.78 Cr | 75.55 Cr |
| Power & Fuel Cost | 4.6 Cr | 4.62 Cr | 5.75 Cr | 6.14 Cr |
| Electricity & Power | 4.6 Cr | 4.62 Cr | 5.75 Cr | 6.14 Cr |
| Employee Cost | 91.59 Cr | 96.78 Cr | 107 Cr | 118.53 Cr |
| Salaries, Wages & Bonus | 80.3 Cr | 87.75 Cr | 97.56 Cr | 107.88 Cr |
| Contributions to EPF & Pension Funds | 5.91 Cr | 4.04 Cr | 4.36 Cr | 5.04 Cr |
| Workmen and Staff Welfare Expenses | 5.38 Cr | 3.12 Cr | 3.11 Cr | 3.81 Cr |
| Other Manufacturing Expenses | 25.76 Cr | 134.28 Cr | 180.31 Cr | 140.23 Cr |
| Processing Charges | 3.12 Cr | 3.2 Cr | 3.57 Cr | 4.44 Cr |
| General and Administration Expenses | 262.51 Cr | 85.92 Cr | 154.1 Cr | 207.41 Cr |
| Rent , Rates & Taxes | 15.89 Lk | 17.07 Lk | 13.64 Lk | 38.01 Lk |
| Insurance | 1.43 Cr | 1.51 Cr | 75.94 Lk | 1.2 Cr |
| Printing and stationery | 13.5 Lk | 4.34 Cr | 8.63 Cr | 8.35 Cr |
| Professional and legal fees | 247.78 Cr | 71.49 Cr | 133.75 Cr | 182.29 Cr |
| Traveling and conveyance | 1.88 Cr | 2.53 Cr | 3.88 Cr | 4.03 Cr |
| Miscellaneous Expenses | 3.48 Cr | 2.41 Cr | 5.68 Cr | 7.03 Cr |
| Provision for doubtful debts | 0 | 0 | 0 | 2.05 Cr |
| Loss on disposal of fixed assets(net) | 0 | 0 | 11.29 Lk | 0 |
| Loss on foreign exchange fluctuations | 0 | 83.86 Lk | 2.07 Cr | 2.9 Cr |
| Total Expenditure | 387.94 Cr | 324 Cr | 452.84 Cr | 479.34 Cr |
| Other Income | 5.41 Cr | 6.84 Cr | 10.88 Cr | 29.47 Cr |
| Interest Received | 89.71 Lk | 1.41 Cr | 7.6 Cr | 25.48 Cr |
| Profit on sale of Fixed Assets | 26.39 Lk | 4.89 Cr | 0 | 58.19 Lk |
| Profits on sale of Investments | 56.3 Lk | 0 | 0 | 0 |
| Provision Written Back | 19.93 Lk | 0 | 0 | 0 |
| Foreign Exchange Gains | 3.01 Cr | 0 | 0 | 0 |
| Operating Profit | -129.56 Cr | -179.9 Cr | -203.18 Cr | -374.32 Cr |
| Interest | 10.65 Cr | 13.33 Cr | 7.63 Cr | 1.66 Cr |
| Interest on Term Loan | 10.04 Cr | 12.86 Cr | 7.15 Cr | 15.69 Lk |
| Bank Charges etc | 0 | 0 | 0 | 50 Lk |
| PBDT | -140.22 Cr | -193.23 Cr | -210.81 Cr | -375.98 Cr |
| Depreciation | 10.92 Cr | 10.16 Cr | 11.77 Cr | 12.13 Cr |
| Profit Before Taxation & Exceptional Items | -151.14 Cr | -203.4 Cr | -222.58 Cr | -388.1 Cr |
| Profit Before Tax | -151.14 Cr | -203.4 Cr | -222.58 Cr | -388.1 Cr |
| Profit After Tax | -151.14 Cr | -203.4 Cr | -222.58 Cr | -388.1 Cr |
| Consolidated Net Profit | -151.14 Cr | -203.4 Cr | -222.58 Cr | -388.1 Cr |
| Profit Balance B/F | -1019.27 Cr | -1168.88 Cr | -1370.58 Cr | -1591.81 Cr |
| Appropriations | -1170.41 Cr | -1372.28 Cr | -1593.17 Cr | -1979.92 Cr |
| Other Appropriation | -1.53 Cr | -1.7 Cr | -1.35 Cr | -18.74 Lk |
| Earnings Per Share | -5.77 | -7.48 | -6.86 | -11.96 |
| Adjusted EPS | -5.77 | -7.48 | -6.86 | -11.96 |
CONSOLIDATED CASH FLOW FOR SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED
| Year End | Mar 2023 | Mar 2024 | ||
|---|---|---|---|---|
| No of Months | 12 months | 12 months | months | months |
| Profit Before Tax | -222.58 Cr | -386.83 Cr | 0 | 0 |
| Adjustment | 6.99 Cr | -10.91 Cr | 0 | 0 |
| Changes In working Capital | 141.11 Cr | -27.33 Cr | 0 | 0 |
| Cash Flow after changes in Working Capital | -74.48 Cr | -425.08 Cr | 0 | 0 |
| Cash Flow from Operating Activities | -69.12 Cr | -429.19 Cr | 0 | 0 |
| Cash Flow from Investing Activities | -548.28 Cr | 391.53 Cr | 0 | 0 |
| Cash Flow from Financing Activitie | 616.76 Cr | 42.41 Cr | 0 | 0 |
| Net Cash Inflow / Outflow | -64.06 Lk | 4.74 Cr | 0 | 0 |
| Opening Cash & Cash Equivalents | 1.22 Cr | 58.36 Lk | 0 | 0 |
| Effect of Foreign Exchange Fluctuations | 0 | 20,000 | 0 | 0 |
| Closing Cash & Cash Equivalent | 58.36 Lk | 5.33 Cr | 0 | 0 |
STANDALONE CASH FLOW FOR SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED
| Year End | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| No of Months | 12 months | 12 months | 12 months | 12 months |
| Profit Before Tax | -151.14 Cr | -203.4 Cr | -222.58 Cr | -388.1 Cr |
| Adjustment | 49.64 Cr | 16.67 Cr | 6.99 Cr | -11.33 Cr |
| Changes In working Capital | -47.88 Cr | -26.05 Cr | 141.11 Cr | -25.88 Cr |
| Cash Flow after changes in Working Capital | -149.37 Cr | -212.78 Cr | -74.48 Cr | -425.32 Cr |
| Cash Flow from Operating Activities | -151.9 Cr | -208.23 Cr | -69.12 Cr | -429.43 Cr |
| Cash Flow from Investing Activities | 1.56 Cr | -29.17 Cr | -548.28 Cr | 391.11 Cr |
| Cash Flow from Financing Activitie | 159.28 Cr | 229.32 Cr | 616.76 Cr | 42.8 Cr |
| Net Cash Inflow / Outflow | 8.95 Cr | -8.08 Cr | -64.06 Lk | 4.48 Cr |
| Opening Cash & Cash Equivalents | 35.23 Lk | 9.3 Cr | 1.22 Cr | 58.36 Lk |
| Effect of Foreign Exchange Fluctuations | 17,000 | -17,000 | 0 | 0 |
| Closing Cash & Cash Equivalent | 9.3 Cr | 1.22 Cr | 58.36 Lk | 5.06 Cr |
CONSOLIDATED BALANCE SHEET FOR SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED
| YEAR | Mar 2023 | Mar 2024 | ||
|---|---|---|---|---|
| Share Capital | 32.45 Cr | 32.45 Cr | 0 | 0 |
| Equity - Authorised | 42.5 Cr | 42.5 Cr | 0 | 0 |
| Equity - Issued | 32.45 Cr | 32.45 Cr | 0 | 0 |
| Equity Paid Up | 32.45 Cr | 32.45 Cr | 0 | 0 |
| Face Value | 1 | 1 | ||
| Total Reserves | 480.32 Cr | 93.3 Cr | 0 | 0 |
| Securities Premium | 2038.16 Cr | 2038.16 Cr | 0 | 0 |
| Profit & Loss Account Balance | -1591.81 Cr | -1978.84 Cr | 0 | 0 |
| General Reserves | 33.98 Cr | 33.98 Cr | 0 | 0 |
| Reserve excluding Revaluation Reserve | 480.32 Cr | 93.3 Cr | 0 | 0 |
| Shareholder's Funds | 512.78 Cr | 125.76 Cr | 0 | 0 |
| Deferred Tax Assets / Liabilities | 0 | -1.26 Cr | 0 | 0 |
| Deferred Tax Assets | 27.9 Cr | 29.76 Cr | 0 | 0 |
| Deferred Tax Liability | 27.9 Cr | 28.5 Cr | 0 | 0 |
| Other Long Term Liabilities | 130.27 Cr | 118.18 Cr | 0 | 0 |
| Long Term Provisions | 8.14 Cr | 6.05 Cr | 0 | 0 |
| Total Non-Current Liabilities | 138.4 Cr | 122.97 Cr | 0 | 0 |
| Trade Payables | 148.25 Cr | 142.29 Cr | 0 | 0 |
| Sundry Creditors | 148.25 Cr | 142.29 Cr | 0 | 0 |
| Other Current Liabilities | 24.15 Cr | 61.88 Cr | 0 | 0 |
| Advances received from customers | 11,000 | 3,000 | 0 | 0 |
| Interest Accrued But Not Due | 0 | 7.11 Lk | 0 | 0 |
| Share Application Money | 21,000 | 0 | 0 | 0 |
| Short Term Borrowings | 5.1 Lk | 47 Cr | 0 | 0 |
| Secured ST Loans repayable on Demands | 5.1 Lk | 47 Cr | 0 | 0 |
| Working Capital Loans- Sec | 5.1 Lk | 47 Cr | 0 | 0 |
| Short Term Provisions | 6.49 Cr | 13.89 Cr | 0 | 0 |
| Provision for Tax | 0 | 1.65 Cr | 0 | 0 |
| Total Current Liabilities | 178.95 Cr | 265.06 Cr | 0 | 0 |
| Total Liabilities | 830.13 Cr | 513.78 Cr | 0 | 0 |
| Gross Block | 146.22 Cr | 157.14 Cr | 0 | 0 |
| Less: Accumulated Depreciation | 40.47 Cr | 49.6 Cr | 0 | 0 |
| Net Block | 105.75 Cr | 107.53 Cr | 0 | 0 |
| Capital Work in Progress | 1.87 Cr | 1.27 Cr | 0 | 0 |
| Long Term Loans & Advances | 64.8 Cr | 67.67 Cr | 0 | 0 |
| Other Non Current Assets | 177.61 Cr | 25.4 Cr | 0 | 0 |
| Total Non-Current Assets | 375.16 Cr | 244.4 Cr | 0 | 0 |
| Currents Investments | 290.9 Cr | 1.8 Cr | 0 | 0 |
| Quoted | 95.5 Cr | 1.8 Cr | 0 | 0 |
| Sundry Debtors | 32.71 Cr | 15.53 Cr | 0 | 0 |
| Debtors more than Six months | 0 | 6.55 Cr | 0 | 0 |
| Debtors Others | 32.71 Cr | 11.04 Cr | 0 | 0 |
| Cash and Bank | 111.58 Cr | 155.33 Cr | 0 | 0 |
| Cash in hand | 22,000 | 32,000 | 0 | 0 |
| Balances at Bank | 111.57 Cr | 155.33 Cr | 0 | 0 |
| Other Current Assets | 3.98 Cr | 42.24 Cr | 0 | 0 |
| Interest accrued on Investments | 63.29 Lk | 14.05 Cr | 0 | 0 |
| Prepaid Expenses | 3.33 Cr | 4.82 Cr | 0 | 0 |
| Short Term Loans and Advances | 15.8 Cr | 54.48 Cr | 0 | 0 |
| Advances recoverable in cash or in kind | 4.58 Cr | 4.35 Cr | 0 | 0 |
| Total Current Assets | 454.96 Cr | 269.39 Cr | 0 | 0 |
| Net Current Assets (Including Current Investments) | 276.02 Cr | 4.33 Cr | 0 | 0 |
| Total Assets | 830.13 Cr | 513.78 Cr | 0 | 0 |
| Contingent Liabilities | 83.57 Cr | 83.57 Cr | 0 | 0 |
| Total Debt | 5.1 Lk | 47 Cr | 0 | 0 |
| Book Value | 15.8 | 3.88 | ||
| Adjusted Book Value | 15.8 | 3.88 |
STANDALONE BALANCE SHEET FOR SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED
| YEAR | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| Share Capital | 26.21 Cr | 27.19 Cr | 32.45 Cr | 32.45 Cr |
| Equity - Authorised | 32.5 Cr | 42.5 Cr | 42.5 Cr | 42.5 Cr |
| Equity - Issued | 26.21 Cr | 27.19 Cr | 32.45 Cr | 32.45 Cr |
| Equity Paid Up | 26.21 Cr | 27.19 Cr | 32.45 Cr | 32.45 Cr |
| Face Value | 1 | 1 | 1 | 1 |
| Total Reserves | -194.46 Cr | -230.22 Cr | 480.32 Cr | 92.4 Cr |
| Securities Premium | 940.45 Cr | 1106.38 Cr | 2038.16 Cr | 2038.16 Cr |
| Profit & Loss Account Balance | -1168.88 Cr | -1370.58 Cr | -1591.81 Cr | -1979.73 Cr |
| General Reserves | 33.98 Cr | 33.98 Cr | 33.98 Cr | 33.98 Cr |
| Reserve excluding Revaluation Reserve | -194.46 Cr | -230.22 Cr | 480.32 Cr | 92.4 Cr |
| Shareholder's Funds | -168.25 Cr | 31.23 Cr | 512.78 Cr | 124.86 Cr |
| Secured Loans | 112.5 Cr | 0 | 0 | 0 |
| Term Loans - Banks | 112.5 Cr | 75 Cr | 0 | 0 |
| Unsecured Loans | 4.22 Cr | 0 | 0 | 0 |
| Deferred Tax Assets | 20.63 Cr | 15.56 Cr | 27.9 Cr | 27.04 Cr |
| Deferred Tax Liability | 20.63 Cr | 15.56 Cr | 27.9 Cr | 27.04 Cr |
| Other Long Term Liabilities | 39.24 Cr | 69.28 Cr | 130.27 Cr | 111.54 Cr |
| Long Term Provisions | 8.63 Cr | 8.15 Cr | 8.14 Cr | 6.05 Cr |
| Total Non-Current Liabilities | 164.59 Cr | 77.43 Cr | 138.4 Cr | 117.59 Cr |
| Trade Payables | 99.06 Cr | 72.19 Cr | 148.25 Cr | 149.82 Cr |
| Sundry Creditors | 99.06 Cr | 72.19 Cr | 148.25 Cr | 149.82 Cr |
| Other Current Liabilities | 48.54 Cr | 93.96 Cr | 24.15 Cr | 43.52 Cr |
| Advances received from customers | 28.7 Lk | 2.92 Lk | 11,000 | 3,000 |
| Interest Accrued But Not Due | 1.93 Cr | 57.21 Lk | 0 | 7.11 Lk |
| Share Application Money | 21,000 | 21,000 | 21,000 | 0 |
| Short Term Borrowings | 80 Cr | 0 | 5.1 Lk | 47 Cr |
| Secured ST Loans repayable on Demands | 0 | 0 | 5.1 Lk | 47 Cr |
| Working Capital Loans- Sec | 0 | 0 | 5.1 Lk | 47 Cr |
| Commercial Borrowings- Unsec | 80 Cr | 0 | 0 | 0 |
| Short Term Provisions | 5.75 Cr | 5.28 Cr | 6.49 Cr | 3.55 Cr |
| Total Current Liabilities | 233.35 Cr | 171.43 Cr | 178.95 Cr | 243.89 Cr |
| Total Liabilities | 229.69 Cr | 280.08 Cr | 830.13 Cr | 486.33 Cr |
| Gross Block | 122.51 Cr | 133.15 Cr | 146.22 Cr | 151.86 Cr |
| Less: Accumulated Depreciation | 31.95 Cr | 41.28 Cr | 40.47 Cr | 49.22 Cr |
| Net Block | 90.56 Cr | 91.87 Cr | 105.75 Cr | 102.65 Cr |
| Capital Work in Progress | 5.23 Cr | 3.72 Cr | 1.87 Cr | 1.27 Cr |
| Non Current Investments | 0 | 0 | 0 | 41.69 Lk |
| Long Term Investment | 0 | 0 | 0 | 41.69 Lk |
| Unquoted | 0 | 0 | 0 | 41.69 Lk |
| Long Term Loans & Advances | 70.64 Cr | 67.83 Cr | 64.8 Cr | 67.67 Cr |
| Other Non Current Assets | 14.8 Lk | 22.87 Cr | 177.61 Cr | 25.4 Cr |
| Total Non-Current Assets | 166.58 Cr | 208.93 Cr | 375.16 Cr | 239.93 Cr |
| Currents Investments | 6.43 Cr | 11.66 Cr | 290.9 Cr | 1.8 Cr |
| Quoted | 0 | 0 | 0 | 1.8 Cr |
| Unquoted | 0 | 0 | 0 | 41.69 Lk |
| Sundry Debtors | 17.58 Cr | 27.74 Cr | 32.71 Cr | 15.53 Cr |
| Debtors more than Six months | 0 | 0 | 0 | 6.55 Cr |
| Debtors Others | 17.58 Cr | 27.74 Cr | 32.71 Cr | 11.04 Cr |
| Cash and Bank | 9.31 Cr | 1.23 Cr | 111.58 Cr | 155.06 Cr |
| Cash in hand | 45,000 | 34,000 | 22,000 | 32,000 |
| Balances at Bank | 9.31 Cr | 1.22 Cr | 111.57 Cr | 155.06 Cr |
| Other Current Assets | 8.1 Cr | 2.5 Cr | 3.98 Cr | 19.58 Cr |
| Interest accrued on Investments | 1,000 | 0 | 63.29 Lk | 14.05 Cr |
| Prepaid Expenses | 4.79 Cr | 2.48 Cr | 3.33 Cr | 4.28 Cr |
| Short Term Loans and Advances | 21.7 Cr | 28.02 Cr | 15.8 Cr | 54.43 Cr |
| Advances recoverable in cash or in kind | 79.61 Lk | 3.91 Cr | 4.58 Cr | 4.3 Cr |
| Total Current Assets | 63.11 Cr | 71.15 Cr | 454.96 Cr | 246.41 Cr |
| Net Current Assets (Including Current Investments) | -170.24 Cr | -100.28 Cr | 276.02 Cr | 2.52 Cr |
| Total Assets | 229.69 Cr | 280.08 Cr | 830.13 Cr | 486.33 Cr |
| Contingent Liabilities | 188.09 Cr | 83.57 Cr | 83.57 Cr | 83.57 Cr |
| Total Debt | 234.76 Cr | 75 Cr | 5.1 Lk | 47 Cr |
| Book Value | -6.42 | -7.47 | 0 | 3.85 |
| Adjusted Book Value | -6.42 | -7.47 | 15.8 | 3.85 |
FINANCIAL RATIOS (CONSOLIDATED) FOR SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED
| YEAR | Mar 2023 | Mar 2024 | ||
|---|---|---|---|---|
| Operational & Financial Ratios | ||||
| Earnings Per Share (Rs) | -6.86 | -11.93 | ||
| CEPS(Rs) | -6.5 | -11.55 | ||
| Book NAV/Share(Rs) | 15.8 | 3.88 | ||
| Tax Rate(%) | 0 | -0.1 | ||
| Margin Ratios | ||||
| Core EBITDA Margin(%) | -89.65 | -532.26 | ||
| EBIT Margin(%) | -90.02 | -509.81 | ||
| Pre Tax Margin(%) | -93.22 | -512.05 | ||
| PAT Margin (%) | -93.22 | -512.56 | ||
| Cash Profit Margin (%) | -88.29 | -496 | ||
| Performance Ratios | ||||
| ROA(%) | -26.81 | -57.63 | ||
| ROE(%) | -43.41 | -121.28 | ||
| ROCE(%) | -41.91 | -112.35 | ||
| Asset Turnover(x) | 0.29 | 0.11 | ||
| Sales/Fixed Asset(x) | 1.63 | 0.5 | ||
| Working Capital/Sales(x) | 0.87 | 17.46 | ||
| Efficiency Ratios | ||||
| Fixed Capital/Sales(x) | 0.61 | 2.01 | ||
| Receivable days | 50.01 | 116.55 | ||
| Valuation Parameters | ||||
| PCE(x) | -27.63 | -32.04 | ||
| Price/Book(x) | 11.36 | 95.47 | ||
| EV/Net Sales(x) | 23.92 | 157.49 | ||
| EV/Core EBITDA(x) | -28.11 | -31.93 | ||
| EV/EBIT(x) | -26.57 | -30.89 | ||
| EV/CE(x) | 11.14 | 68.87 | ||
| M Cap / Sales | 24.39 | 158.92 | ||
| Growth Ratio | ||||
| Net Sales Growth(%) | 0 | -68.36 | ||
| Core EBITDA Growth(%) | 0 | -83.4 | ||
| EBIT Growth(%) | 0 | -79.18 | ||
| PAT Growth(%) | 0 | -73.96 | ||
| EPS Growth(%) | 0 | -73.96 | ||
| Financial Stability Ratios | ||||
| Total Debt/Equity(x) | 0 | 0.37 | ||
| Current Ratio(x) | 2.54 | 1.02 | ||
| Quick Ratio(x) | 2.54 | 1.02 | ||
| Interest Cover(x) | -28.15 | -227.27 | ||
FINANCIAL RATIOS (STANDALONE) FOR SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED
| YEAR | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| Operational & Financial Ratios | ||||
| Earnings Per Share (Rs) | -5.77 | -7.48 | -6.86 | -11.96 |
| CEPS(Rs) | -5.35 | -7.11 | -6.5 | -11.59 |
| Book NAV/Share(Rs) | -6.42 | -7.47 | 15.8 | 3.85 |
| Margin Ratios | ||||
| Core EBITDA Margin(%) | -53.36 | -136.07 | -89.65 | -534.5 |
| EBIT Margin(%) | -55.54 | -138.48 | -90.02 | -511.55 |
| Pre Tax Margin(%) | -59.75 | -148.2 | -93.22 | -513.74 |
| PAT Margin (%) | -59.75 | -148.2 | -93.22 | -513.74 |
| Cash Profit Margin (%) | -55.43 | -140.79 | -88.29 | -497.69 |
| Performance Ratios | ||||
| ROA(%) | -60.18 | -79.8 | -40.1 | -58.96 |
| ROE(%) | 0 | 0 | -143.72 | -121.73 |
| ROCE(%) | -244.77 | -225.57 | -69.44 | -112.88 |
| Asset Turnover(x) | 1.01 | 0.54 | 0.43 | 0.11 |
| Sales/Fixed Asset(x) | 1.96 | 1.07 | 1.71 | 0.51 |
| Working Capital/Sales(x) | -1.49 | -1.37 | 0.87 | 29.99 |
| Efficiency Ratios | ||||
| Fixed Capital/Sales(x) | 0.51 | 0.93 | 0.58 | 1.97 |
| Receivable days | 24.26 | 60.25 | 46.2 | 116.55 |
| Payable days | 350.47 | 0 | 0 | 0 |
| Valuation Parameters | ||||
| PCE(x) | -26.48 | -41.77 | -27.63 | -31.93 |
| Price/Book(x) | -22.07 | -39.75 | 11.36 | 96.16 |
| EV/Net Sales(x) | 15.57 | 59.34 | 23.92 | 157.49 |
| EV/Core EBITDA(x) | -30.4 | -45.27 | -28.11 | -31.79 |
| EV/EBIT(x) | -28.04 | -42.85 | -26.57 | -30.79 |
| EV/CE(x) | 17.15 | 29.08 | 6.88 | 69.23 |
| M Cap / Sales | 14.68 | 58.81 | 24.39 | 158.92 |
| Growth Ratio | ||||
| Net Sales Growth(%) | 229.31 | -45.74 | 73.98 | -68.36 |
| Core EBITDA Growth(%) | 56.85 | -38.85 | -12.94 | -84.23 |
| EBIT Growth(%) | 54.64 | -35.29 | -13.09 | -79.79 |
| PAT Growth(%) | 51.62 | -34.58 | -9.43 | -74.36 |
| EPS Growth(%) | 51.62 | -29.71 | 8.32 | -74.37 |
| Financial Stability Ratios | ||||
| Total Debt/Equity(x) | -1.4 | -0.37 | 0 | 0.38 |
| Current Ratio(x) | 0.27 | 0.42 | 2.54 | 1.01 |
| Quick Ratio(x) | 0.27 | 0.42 | 2.54 | 1.01 |
| Interest Cover(x) | -13.19 | -14.26 | -28.15 | -233.48 |
| Total Debt/Mcap(x) | 0.06 | 0.01 | 0 | 0 |
SHARE HOLDING PATTERN FOR SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED
| Date | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoters % | 69.09 | 69.09 | 65.67 | 65.67 | 65.67 | 65.67 | 65.67 | 65.67 | 65.67 | 65.67 |
| FII % | 2.40 | 2.38 | 3.54 | 3.64 | 3.64 | 3.67 | 3.30 | 3.24 | 2.64 | 2.15 |
| DII % | 0.52 | 0.52 | 0.43 | 0.42 | 0.42 | 0.42 | 0.43 | 0.42 | 0.09 | 0.11 |
| Public % | 27.75 | 27.77 | 30.15 | 30.06 | 30.06 | 30.00 | 30.36 | 30.42 | 31.52 | 31.96 |
PEER COMPARISON FOR SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED
CORPORATE ACTIONS FOR SUN PHARMA
| Exchange Date | Purpose | Book Closure Dates |
|---|---|---|
| BSE 25-Oct-2024 | Board Meeting - Quarterly Results | 04-Nov-2024 |
| BSE 29-Jul-2024 | Board Meeting - Quarterly Results | 05-Aug-2024 |
| BSE 17-May-2024 | Board Meeting - Audited Results | 24-May-2024 |
| BSE 24-Jan-2024 | Board Meeting - Quarterly Results | 05-Feb-2024 |
| BSE 27-Oct-2023 | Board Meeting - Quarterly Results | 06-Nov-2023 |
| BSE 31-Jul-2023 | Board Meeting - Quarterly Results | 07-Aug-2023 |
| BSE 17-May-2023 | Board Meeting - Audited Results Inter alia, to consider and approve and evaluate various options or proposals for raising funds through any of the permissible modes, subject to the receipt of necessary approvals | 22-May-2023 |
| BSE 15-May-2023 | Board Meeting - Audited Results | 22-May-2023 |
| BSE 06-Feb-2023 | Board Meeting - Quarterly Results | 13-Feb-2023 |
| BSE 28-Oct-2022 | Board Meeting - Quarterly Results | 07-Nov-2022 |
| BSE 01-Aug-2022 | Board Meeting - Quarterly Results & Inter alia, to consider and evaluate various options or proposals for raising funds through any of the permissible modes, subject to the receipt of necessary approvals.531433 Sungold Capital Ltd. 09/08/2022 Quarterly Results | 08-Aug-2022 |
| BSE 09-May-2022 | Board Meeting - Audited Results | 17-May-2022 |
| BSE 27-Jan-2022 | Board Meeting - Quarterly Results | 04-Feb-2022 |
| BSE 25-Oct-2021 | Board Meeting - Quarterly Results | 01-Nov-2021 |
| BSE 03-Sep-2021 | AGM - A.G.M. | 29-Sep-2021 29-Sep-2021 |
| BSE 03-Sep-2021 | Book Closure - A.G.M. | 23-Sep-2021 29-Sep-2021 |
| BSE 30-Aug-2021 | Board Meeting - SUN PHARMA ADVANCED RESEARCH COMPANY LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/09/2021 ,inter alia, to consider and approve / evaluate various options or proposals for raising funds through any of the permissible modes, subject to the receipt of necessary approvals. | 01-Sep-2021 |
CORPORATE ANNOUNCEMENTS FOR SUN PHARMA
| Exchange Date | Category File | Description |
|---|---|---|
| BSE 25-Oct-2024 | Intimation FILE | Board Meeting Intimation for Approval Of Unaudited Financial Results Of The Company SUN PHARMA ADVANCED RESEARCH COMPANY LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2024 inter alia to consider and approve Unaudited Financial Results of the Company for the quarter and half year ended September 30 2024. |
| BSE 15-Oct-2024 | General Announcements FILE | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Intimation regarding Compliance Certificate |
| BSE 25-Sep-2024 | Intimation FILE | Closure of Trading Window Intimation regarding Closure of Trading Window |
| BSE 24-Sep-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Change in Management Revised Disclosure under Regulation 30 (LODR) |
| BSE 14-Aug-2024 | Outcome FILE | Shareholder Meeting / Postal Ballot-Scrutinizer''s Report Intimation regarding Voting results and Scrutinizer Report |
| BSE 12-Aug-2024 | Outcome FILE | Shareholder Meeting / Postal Ballot-Outcome of AGM Outcome of 19th Annual General Meeting including Chairmans Speech |
| BSE 06-Aug-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Newspaper Publication Intimation regarding newspaper advertisement |
| BSE 05-Aug-2024 | Outcome FILE | Financial Results For The Quarter Ended June 30 2024 Financial Results for the quarter ended June 30 2024 |
| BSE 05-Aug-2024 | Outcome FILE | Board Meeting Outcome for Outcome Of Board Meeting For Unaudited Financial Results For The Quarter Ended June 30 2024 Outcome of Board Meeting for Unaudited Financial Results for the quarter ended June 30 2024 |
| BSE 03-Aug-2024 | General Announcements FILE | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation regarding issuance of new share certificate issued on duplication |
| BSE 29-Jul-2024 | Intimation FILE | Board Meeting Intimation for The Approval Of The Financial Results Of The Company For The First Quarter Ended June 30 2024 SUN PHARMA ADVANCED RESEARCH COMPANY LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2024 inter alia to consider and approve the Standalone and Consolidated Financial Results of the Company for the first quarter ended June 30 2024 |
| BSE 26-Jul-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Change in Management Dr. Nitin Dharmadhikari has been re-designated as Chief Operation Officer (COO) of the Company |
| BSE 26-Jul-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Change in Management Dr. Mudgal Kothekar Vice President and Dr. Sandeep Inamdar Vice President - Clinical Development have been designated as senior management personnel of the Company w.e.f July 26 2024 |
| BSE 19-Jul-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Newspaper Publication Newspaper Advertisement for 19th Annual General Meeting of the Company and related information. |
| BSE 18-Jul-2024 | General Announcements FILE | Business Responsibility and Sustainability Reporting (BRSR) Business Responsibility and Sustainability Report for the financial year 2023-24 |
| BSE 18-Jul-2024 | Intimation FILE | Notice Of 19Th Annual General Meeting Of The Company To Be Held On Monday August 12 2024 At 04:00 PM Annual Report for the Financial Year 2023-24 along with the Notice of 19th Annual General Meeting. |
| BSE 18-Jul-2024 | General Announcements FILE | Reg. 34 (1) Annual Report. Submission of the Annual Report of the Company for the financial year 2023-24 including Notice of 19th AGM to be held on August 12 2024. |
| BSE 15-Jul-2024 | General Announcements FILE | Announcement Under Regulation 30 Of LODR Intimation under regulation 30 of LODR - Retirement of Director upon completion of term. |
| BSE 15-Jul-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Change in Directorate Disclosure under Regulation 30 of LODR regarding appointment of Ms. Vidhi Shanghvi as an Additional Non-Executive Non-Independent Director |
| BSE 09-Jul-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Newspaper Publication Newspaper Advertisement - 19th Annual General Meeting of the Company and other related information |
| BSE 08-Jul-2024 | General Announcements FILE | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 As attached |
| BSE 08-Jul-2024 | Intimation FILE | Intimation Of The 19Th Annual Annual General Meeting Of The Company The 19th Annual General Meeting of the Company will be held on Monday August 12 2024 at 04:00 pm (IST) through Video Conferencing / other Audio-Visual Means |
| BSE 26-Jun-2024 | Intimation FILE | Closure of Trading Window Intimation regarding closure of Trading Window |
| BSE 27-May-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Newspaper Publication As attached |
| BSE 24-May-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Change in Management As attached |
| BSE 24-May-2024 | General Announcements FILE | Announcement Under Regulation 30(5) Of SEBI (LODR) Regulations 2015 As attached |
| BSE 24-May-2024 | Compliance FILE | Statement Of Deviation For Quarter Ended March 31 2024 As attached |
| BSE 24-May-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Raising of Funds As attached |
| BSE 24-May-2024 | General Announcements FILE | Statement Of Deviation & Variation For Quarter Ended March 31 2024 As attached |
| BSE 24-May-2024 | Outcome FILE | Board Meeting Outcome for Board Meeting Outcome For Audited Financial Results Outcome for Board Meeting |
INSIDER TRADING FOR SUN PHARMA
| Exchange Dates | Activity | Qty & Price (%) | Person / Organisation |
|---|---|---|---|
| BSE 21-Mar-2022 21-Mar-2022 | Buy Conversion of security | 8,426,970 @ 0.00 (2.77 %) | Dilip S Shanghvi |
| BSE 21-Mar-2022 21-Mar-2022 | Sell Conversion of security | 8,426,970 @ 0.00 (5.93 %) | Dilip S Shanghvi |
BULK BLOCK DEALS FOR SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED
| Exchange Dates | Activity | Qty & Price (%) | Person / Organisation |
|---|---|---|---|
| BSE 19-Sep-2022 | Sell BLOCK | 1,119,999 @ 221.30 | ISHARES CORE EMERGING MARKETS MAURITIUS CO |
| BSE 19-Sep-2022 | Buy BLOCK | 1,119,999 @ 221.30 | ISHARES CORE MSCI EMERGING MARKETS ETF |
| BSE 19-Sep-2022 | Sell BLOCK | 71,632 @ 221.30 | ISHARES INDIA SC MAURITIUS COMPANY |
| BSE 19-Sep-2022 | Buy BLOCK | 71,632 @ 221.30 | ISHARES MSCI INDIA SMALL-CAP ETF |
DIVIDEND BY SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED
No dividend details found
SPLIT / BONUS BY SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED
No Split / Bonus details found
Data feed Source : www.accordfintech.com, NSE DATA Feed & BSE Data Feed
